Save up -80% on Enfuvirtide
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Fuzeon
|$3,558.10||1 kit (60 vials) 90mg|
|Price with discount in nearest pharmacy. Price may vary.|
We offer free Fuzeon coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Enfuvirtide every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Enfuvirtide volume of distribution
Enfuvirtide exhibits a small volume of distribution (5.48 L), low systemic clearance (1.4 L/h) and high plasma protein binding (92%). Less than 17% of enfuvirtide is converted to a minimally active deaminated form of the parent drug.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Enfuvirtide
Enfuvirtide is a 36 residue synthetic peptide that inhibits HIV-1 fusion with CD4 cells. It is an N-terminal acetylated, C-terminal amide. As an HIV fusion inhibitor, it is the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection.
Enfuvirtide mechanism of action
Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected. Enfuvirtide is a biomimetic peptide that was rationally designed to mimic components of the HIV-1 fusion machinery and displace them, preventing normal fusion. ; ;
Dosage forms of Enfuvirtide
|Powder and solvent for solution for injection||Subcutaneous use||90 mg/ml|
|Powder for solution||subcutaneous||108 mg|
Envelope polyprotein GP160 precursor[Contains: Exterior membrane glycoprotein,GP120, Transmembrane glycoprotein,GP41]
Hoffmann La Roche Limited
Human Immunodeficiency Virus
Indication of Enfuvirtide
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.
Toxicity of Enfuvirtide
Enfuvirtide has not been reported to cause serum aminotransferase elevations at rates higher than in controls receiving similar antiretroviral therapy. No instances of clinically apparent liver injury due to enfuvirtide have appeared in the published literature. Enfuvirtide has, however, not been a widely used agent. Partially because it requires twice daily parenteral injections. Enfuvirtide is associated with rare (<1%) instances of hypersensitivity reactions with eosinophilia, rash and systemic symptoms which can be accompanied by transient serum aminotransferase elevations, but other symptoms of hypersensitivity dominate the clinical picture.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Enfuvirtide on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.